NYC Congestion Pricing, Stem Cell Therapy

Dr. Silviu Itescu, CEO of Mesoblast, shares insights into the breakthrough FDA approval of their stem cell therapy targeted for pediatric graft versus host disease. He delves into the therapy's promising market potential and its unique anti-inflammatory responses. The conversation also touches on the complexities surrounding commercialization, including ethical and regulatory challenges. Alongside this, urban traffic solutions, like NYC's congestion pricing, are examined for their transformative impacts on public transit and urban sustainability.